gs3-02. updated overall survival (os) results from the phase 3 phoebe trial
Published 1 year ago • 59 plays • Length 8:15Download video MP4
Download video MP3
Similar videos
-
13:53
gs2-01: "overall survival subgroup analysis by metastatic site from the phase3 monaleesa-2..."
-
12:19
sabcs 2022: updated survival results of the randomized, phase 3 study destiny-breast03 q & a
-
6:44
overall survival (os) results of the phase iii monaleesa-3 trial
-
5:10
paloma-3: overall survival (os) with palbociclib plus fulvestrant in hr ,her2_ abc
-
36:38
pl2 triple negative breast cancer - pitfalls and progress lisa a. carey
-
20:37
gs2-02: "elacestrant, an oral selective estrogen receptor degrader (serd), vs investigator’s..."
-
28:32
dr. reuben harris | san antonio breast cancer symposium 2022 | basic science workshop
-
43:05
dr. puja sapra | san antonio breast cancer symposium 2022 | educational session
-
14:05
gs2-00: "correlative analysis of overall survival by intrinsic subtype across the monaleesa-2..."
-
15:26
gs3-04: discussant
-
2:16
sabcs 2022: destiny-breast02 destiny-breast03
-
16:44
phase iii katherine clinical trial
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
15:53
gs3 -05: "fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection..."
-
15:52
gs3-01: "trastuzumab deruxtecan vs trastuzumab emtansine in patients with her2 metastatic..."
-
1:00
highlights from the san antonio breast cancer symposium 2022
-
29:57
dr. prudence francis | premenopausal er breast cancer: past, present, future | sabcs 2022
-
1:01
what emerald phase iii trial could mean for breast cancer patients | virginia kaklamani, md
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
2:57
key data from the san antonio breast cancer symposium (sabcs) 2022
-
1:01:02
report back from san antonio breast cancer symposium on metastatic breast cancer
-
15:33
gs2-10: "nimbus: a phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated..."